Difference between revisions of "Part:BBa K4040021"
| Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K4040021 short</partinfo> | <partinfo>BBa_K4040021 short</partinfo> | ||
| − | + | ===Sequence and Features=== | |
| − | + | <partinfo>BBa_K4040021 SequenceAndFeatures</partinfo> | |
| − | + | ||
| − | < | + | |
===Usage and Biology=== | ===Usage and Biology=== | ||
| + | This part is part of our design of IL-6 complex receptor. We connect TCS (<partinfo>BBa_J18918</partinfo>) behind mil-6R and connect part GAl4_KRAB(<partinfo>BBa_K2446037</partinfo>) downstream of TCS. We used CMV(<partinfo>BBa_I712004</partinfo>) as the promoter. When IL-6 elevates to a certain level in vivo, MIL-6R forms a hexamer complex with GP130 and IL-6 from <partinfo>BBa_K4040020</partinfo>. TEV protease in <partinfo>BBa_K2446037</partinfo> is activated. Then it binds to TCS which connects to the downstream of IL-6R and digests the binding site. Gal4-krab (<partinfo>BBa_K2446037</partinfo>) is released, which modulates the expression of another composite part we designed, <partinfo>BBa_K4040023</partinfo>, and promotes the transformation of macrophages to M2 state by inhibiting the expression of CAR-γ. | ||
| + | [[File:T--NMU China--IL6R-TCS-Gal4-KRAB.jpg|300px|thumb|left|<b>Figure. 1</b>The structure of IL6R-TCS-Gal4-KRAB.]] | ||
| + | [[File:T--NMU China--IL-6R.jpg|550px|thumb|right|<b>Figure. 2</b>The structure and downstream pathway of the composite IL6R.]] | ||
| + | <!-- Add more about the biology of this part here | ||
| + | |||
<!-- --> | <!-- --> | ||
| − | + | ||
| − | + | ||
Revision as of 12:11, 11 October 2021
Synthetic Receptor IL6R-TCS-Gal4-KRAB
Sequence and Features
Assembly Compatibility:
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 1237
Illegal PstI site found at 1414
Illegal PstI site found at 1969
Illegal PstI site found at 2815
Illegal PstI site found at 2974
Illegal PstI site found at 3082 - 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 1237
Illegal PstI site found at 1414
Illegal PstI site found at 1969
Illegal PstI site found at 2815
Illegal PstI site found at 2974
Illegal PstI site found at 3082
Illegal NotI site found at 3323
Illegal NotI site found at 3944
Illegal NotI site found at 4256 - 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 2692
Illegal BamHI site found at 3825 - 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 1237
Illegal PstI site found at 1414
Illegal PstI site found at 1969
Illegal PstI site found at 2815
Illegal PstI site found at 2974
Illegal PstI site found at 3082 - 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 1237
Illegal PstI site found at 1414
Illegal PstI site found at 1969
Illegal PstI site found at 2815
Illegal PstI site found at 2974
Illegal PstI site found at 3082
Illegal NgoMIV site found at 796
Illegal NgoMIV site found at 820
Illegal NgoMIV site found at 892
Illegal NgoMIV site found at 904
Illegal NgoMIV site found at 1754
Illegal NgoMIV site found at 1889 - 1000COMPATIBLE WITH RFC[1000]
Usage and Biology
This part is part of our design of IL-6 complex receptor. We connect TCS (BBa_J18918) behind mil-6R and connect part GAl4_KRAB(BBa_K2446037) downstream of TCS. We used CMV(BBa_I712004) as the promoter. When IL-6 elevates to a certain level in vivo, MIL-6R forms a hexamer complex with GP130 and IL-6 from BBa_K4040020. TEV protease in BBa_K2446037 is activated. Then it binds to TCS which connects to the downstream of IL-6R and digests the binding site. Gal4-krab (BBa_K2446037) is released, which modulates the expression of another composite part we designed, BBa_K4040023, and promotes the transformation of macrophages to M2 state by inhibiting the expression of CAR-γ.
